Kim Chi
Taipei Medical University · BCCA - Vancouver Cancer Centre, BC Canada · BCCA - Vancouver Cancer Centre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kim Chi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:49 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07806747 · Effectiveness of Serious Games on Nursing Students' Clinical ReasoningDo Thi Kim Chi · not yet recruiting · Clinical Reasoning · principal investigator
- Ph2NCT04663997 · 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate CancerCanadian Cancer Trials Group · active not recruiting · Prostate Cancer · study chair
- Ph2NCT03385655 · Prostate Cancer Biomarker Enrichment and Treatment SelectionCanadian Cancer Trials Group · active not recruiting · Prostate Cancer · study chair
- Ph2NCT02905318 · Palbociclib in Patients With Metastatic Castration-Resistant Prostate CancerCanadian Cancer Trials Group · active not recruiting · Prostate Cancer · study chair
- Ph2NCT01331083 · A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate CancerNCIC Clinical Trials Group · completed · Prostate Cancer · study chair
- Ph3NCT01188187 · Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate CancerAchieve Life Sciences · completed · Prostate Cancer · study chair
- Ph2NCT00757692 · Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.British Columbia Cancer Agency · completed · Prostate Cancer · study chair
- Ph1NCT00487786 · Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder CancerAchieve Life Sciences · completed · Neoplasms · principal investigator
- Ph2NCT00486642 · Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyNational Cancer Institute (NCI) · completed · Hormone-Resistant Prostate Cancer, Recurrent Prostate Carcinoma · principal investigator
- Ph2NCT00407251 · Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel ChemotherapyBritish Columbia Cancer Agency · completed · Hormone Refractory Prostate Cancer · study chair
- Ph2NCT00138918 · Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate CancerUniversity of British Columbia · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 11 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:49 UTC. The ranking covers the 200 most relevant of 168 PubMed records, and a shared surname and initials can bring in a namesake. All 168 on PubMed
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med · 20044,719 citationsRCR 102.9
- Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med · 20123,750 citationsRCR 102.0
- Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med · 20113,643 citationsRCR 95.7
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 20212,357 citationsRCR 149.5
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 20201,923 citationsRCR 83.2
- 1,866 citationsRCR 65.3
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med · 20191,331 citationsRCR 51.5
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.N Engl J Med · 20191,279 citationsRCR 51.3
- 1,127 citationsRCR 30.7
- 702 citationsRCR 27.5